Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Large Drop in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 16,400 shares, a decline of 34.4% from the December 15th total of 25,000 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Basilea Pharmaceutica Stock Performance

Shares of Basilea Pharmaceutica stock remained flat at $52.83 on Friday. Basilea Pharmaceutica has a one year low of $38.60 and a one year high of $52.83. The firm’s 50-day moving average is $52.83 and its 200 day moving average is $51.09.

Analyst Ratings Changes

Separately, HC Wainwright upgraded Basilea Pharmaceutica to a “strong-buy” rating in a report on Monday, September 23rd.

View Our Latest Report on BPMUF

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

Further Reading

• Five stocks we like better than Basilea Pharmaceutica
• High Dividend REITs: Are They an Ideal Way to Diversify?
• AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
• Uptrend Stocks Explained: Learn How to Trade Using Uptrends
• TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
• Stock Splits, Do They Really Impact Investors?
• Uber’s NVIDIA Deal and Buybacks Signal Major Upside